Osimertinib (Osi), as the third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC). However, recent studies have found that its acquired resistance severely limits its therapeutic effect. This stud...
Jun-Yuan Huang, Yin-Huang Gao, Shi-Qin Jiang et al.· Toxicology and Applied Pharm...· 0 citations
It is suggested that pharmacological inhibition of ferroptosis by Lip-1 represented a promising strategy against TP-induced BTB disruption and testicular injury.
Song-Xia Lin, Jian-Xun Song, Xiao-Dan Wang et al.· Reproductive Toxicology· 0 citations
The interplay between YAP/TAZ and metabolic reprogramming in cancer is systematically clarified, the core molecular networks through which YAP/TAZ govern each metabolic pathway are delineated, and the current pharmacological inhibitors targeting YAP/TAZ-regulated metabolic networks are summarized.
Yin-Huang Gao, Ming-Hong Chen, Song-Xia Lin et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.